Lisa Low

Matregen Corp. engaged in the development and commercialization of novel Drug Delivery Systems. Its SpinFX technology is a technique used to produce novel structures such as porous tubes, composites, and coatings. The company was founded by Dr. Molly S. Shoichet and Dr. Paul D. Dalton in 2002 and is headquartered in Toronto, Canada.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada.

Giiant Pharma, Inc. is a Canadian preclinical-stage biotech company that specializes in designing gut-restricted small molecule drug therapeutics with various biological targets in gastroenterology. The company is based in Montréal, Canada and was founded by Elizabeth Elizabeth Kwong. The company's proprietary precision delivery technology platform allows for the creation of tissue-specific drugs with improved tolerability and enhanced therapeutic effects. Giiant's first lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug. Maxime Ranger has been the CEO of the company since 2021.

DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada.

RBC Capital Partners Ltd. is a Venture Capital firm, a subsidiary of RBC Dominion Securities, Inc. founded in 1900. RBC Capital Partners Ltd. is headquartered in Toronto, Canada with offices across the globe.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Flosonics Medical develops and operates medical software platform for the management of critically ill patients. The company was founded by Joe Eibl, Jon-Emile Kenny, Andrew Eibl, and Sachit Harish and is headquartered in Sudbury, Canada.

Part of Gilead Sciences, Inc., DELEX Therapeutics, Inc. is a Canadian company that researches and develops inhalation pain treatment products for cancer patients. The company is based in Mississauga, Canada. DELEX Therapeutics was acquired by YM BioSciences, Inc. on May 03, 2005 for $7.60 million.

Part of Thermo Fisher Scientific, Inc., Ionalytics Corp. designs and manufactures ion-filtering equipment and related engineering instruments. The company is based in Ottawa, Canada. Ionalytics was acquired by Thermo Electron Corp. on August 11, 2005.

Millenium Biologix Corp. is focused on the development and commercialization of next generation, skeletal tissue regeneration products and implantable medical devices, initially targeted for orthopedic uses. These products, used alone or in combination configurations, promote the repair and natural healing of human bone and other skeletal tissues such as cartilage. Millenium's strength in developing leading treatments for regenerative medicine is based on its successful integration of three core competencies in advanced biomaterials, biologics and engineering. Its core business activities are focused on tissue engineering products, and on orthobiologicals. It was founded on April 1, 1998 and is headquartered in Kingston, ON.

Adapsyn Bioscience, Inc. operates as a biotechnology company focussed on the discovery and development of novel medicines. The company was founded by Nathan Magarvey and is headquartered in Hamilton, Canada.

Functional Neuromodulation Ltd. operates as a holding company which engages in the design and development of deep brain stimulation therapies for memory and cognitive disorders. It uses a surgically implanted medical device, similar to a pacemaker, to deliver mild electrical pulses to targeted areas of the brain. The company was founded by Andres Lozano in 2010 and is headquartered in Boston, MA.

Interface Biologics, Inc. operates as a commercial stage privately held company that develops transformative biomedical polymer technologies to improve the safety and effectiveness of medical devices. It provides technologies to medical device manufacturers and drug companies. The company was founded by Paul J. Santerre in December 2001 and is headquartered in Toronto, Canada.

Diamond Therapeutics, Inc. is a Canadian clinical-stage drug development company founded in 2018 by Judy Blumstock. The company is based in an undisclosed location and is focused on developing safe, FDA, EMA, and Health Canada approved therapies for neuropsychiatric conditions. The company is developing sub-perceptual, non-hallucinogenic, psychedelic-based treatments that hold potential for use across a broad patient cohort, with the goal of maximizing the positive impact better drugs can have on the mental health crisis. Diamond's mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds.

Tabula Rasa Ventures LLC (Tabula Rasa Ventures) is a venture capital firm founded in 2019 by Marik Hazan. The firm is headquartered in New York.

Neurasic Therapeutics, Inc. develops opiate-sparing and pain-relieving drugs. The company was founded in June 2020 and is headquartered in Westmount, Canada.

SemaThera, Inc. engages in research and development in biotechnology. It develops novel inhibitors against semaphorin 3A (SEMA 3A) for prevention and reversal of diabetic macular edema (DME). The company is headquartered in Montreal, Canada.

Part of Ambrilia Biopharma, Inc., Bioxalis Medica, Inc. is a Canadian company that researches cancer treatment and drugs. The company is based in Montréal, Canada. Bioxalis Medica was acquired by Procyon Biopharma, Inc. on June 30, 2005 for $2.79 million.

Thing Tank LLC provides design, research, and facilitation services. The American company has worked with various companies such as Ono Foods Co, Oglesby & Butler, Molekule, Elp, LTSE, Peloton Technology, Kiba, Chick-fil-A, Steelcase, E2E, Westfield, 3form, Plantronics, Nuko, NRML, and DWR. The private company's services include performance assessment studies, service and store design, user interface, mobile apps, and automatic camera experiences.

Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada.

Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD.

BIOTECanada serves as a national association for Canada's health, industrial and agricultural biotechnology sectors. The company was founded in 1986 and is headquartered in Ottawa, Canada.

EBT Medical, Inc. develops disruptive neurostimulation therapies for pelvic health disorders. The firm’s services include pelvic floor disorders and overactive bladder. The company was founded by Paul Yoo and Sasha John in 2014 and is headquartered in Toronto, Canada.

Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL.